Valuation: Cerus Corporation

Market Cap 455M 407M 378M 344M 647M 43.14B 658M 4.54B 1.78B 22.51B 1.71B 1.67B 72.02B P/E 2026 *
-64.6x
P/E 2027 * -226x
Enterprise Value 460M 411M 382M 347M 654M 43.61B 665M 4.59B 1.8B 22.75B 1.73B 1.69B 72.81B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.63x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.89%
1 week-0.88%
Current month-5.04%
1 month-9.60%
3 months-28.93%
6 months+11.88%
Current year+9.71%
1 week 2.21
Extreme 2.21
2.32
1 month 2.2
Extreme 2.2
2.69
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-30,000 0.0150%
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%-0.88%+42.14%+75.19% 455M
+1.66%+6.28%-19.13%+15.20% 181B
+1.29%+8.77%+0.12%+32.64% 117B
+4.12%+5.87%-20.70%+13.71% 112B
+2.69%+4.34%-44.79%-7.80% 76.56B
+1.56%+6.24%+6.82%+80.66% 65.15B
+2.79%+2.37%+15.93%+68.64% 52.79B
+2.58%+6.02%+3.74%-25.10% 52.78B
+3.43%+6.63%-14.39%+28.39% 43.11B
+1.78%+2.32% - - 32.08B
Average +1.86%+4.47%-3.36%+31.28% 73.34B
Weighted average by Cap. +1.69%+5.70%-11.88%+23.28%

Financials

2026 *2027 *
Net sales 249M 222M 207M 188M 354M 23.59B 360M 2.48B 971M 12.31B 935M 915M 39.38B 272M 242M 225M 205M 385M 25.72B 392M 2.71B 1.06B 13.42B 1.02B 997M 42.94B
Net income -8.77M -7.83M -7.27M -6.62M -12.45M -830M -12.67M -87.36M -34.18M -433M -32.9M -32.2M -1.39B -1.67M -1.49M -1.38M -1.26M -2.37M -158M -2.41M -16.61M -6.5M -82.36M -6.25M -6.12M -264M
Net Debt 5M 4.46M 4.15M 3.77M 7.1M 474M 7.23M 49.83M 19.5M 247M 18.76M 18.37M 791M -13M -11.6M -10.78M -9.81M -18.46M -1.23B -18.79M -130M -50.69M -642M -48.79M -47.75M -2.06B
Projected Income Statement - Annual - Cerus Corporation
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-10-15 US$2.260 +0.89% 2,122,681
26-10-14 US$2.240 -0.88% 2,891,076
26-10-13 US$2.260 0.00% 2,293,133
26-10-12 US$2.260 -1.74% 1,179,807
26-10-09 US$2.300 +0.88% 787,967
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cerus Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.260USD
Average target price
5.125USD
Spread / Average Target
+126.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerus Corporation
  1. Stock Market
  2. Stocks
  3. CERS Stock